Novo Nordisk’s board took the unusual step of replacing its chief executive in May of last year after a period of intensifying competition from both Eli Lilly’s injectable GLP-1 therapies and telehealth providers pushing lower-cost generics. From its mid-2024 peak, the share price declined by more than 50%, reflecting investor concerns over market share erosion, slower growth in its diabetes franchise and uncertainty around its obesity pipeline strategy.

In early January, Novo Nordisk commenced shipments of its FDA-approved oral version of Wegovy, transforming the former subcutaneous therapy into a convenient daily tablet. The company had pre-positioned ample inventory and secured distribution partnerships with major retail and online channels, including Amazon and Costco. Within the first week of launch, approximately 3,100 prescriptions were filled, rising to 8,000 by week two—metrics that signal rapid early adoption among patients deterred by injections.

Analysts note that Novo Nordisk shares trade at roughly 18 times forward earnings, compared with a decade-long average P/E of 27. Even assuming a conservative re-rating to 25 times, and consensus earnings per share of about $3.49 for the year, the implied valuation points to upside of approximately 40% over current levels. Renewed confidence in the oral GLP-1 franchise, combined with sustained market leadership in metabolic disease, underpins a potential rerating back toward historical multiples.